C4 Therapeutics (CCCC) Assets Average (2020 - 2026)

C4 Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $344.0 million for Q1 2026.

• In Q1 2026, Assets Average rose 2.81% year-over-year to $344.0 million; the TTM figure through Mar 2026 stood at $344.0 million (up 2.81% YoY), while the FY2025 annual figure was $354.3 million, down 2.39% from the prior year.
• Assets Average for Q1 2026 stood at $344.0 million, up from $312.3 million in the prior quarter.
• The five-year high for Assets Average was $511.1 million in Q1 2022, with the low at $281.0 million in Q3 2025.
• The 5-year median for Assets Average is $378.6 million (2024), against an average of $385.0 million.
• The sharpest annual moves came in 2022 and 2023: Assets Average surged 32.05% in 2022, then dropped 25.78% in 2023.
• C4 Therapeutics' Assets Average stood at $446.1 million in 2022, then dropped by 20.49% to $354.7 million in 2023, then grew by 2.28% to $362.8 million in 2024, then retreated by 13.93% to $312.3 million in 2025, then increased by 10.15% to $344.0 million in 2026.
• Business Quant data shows CCCC's Assets Average at $344.0 million in Q1 2026, $312.3 million in Q4 2025, and $281.0 million in Q3 2025.